4.5 Article

Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel

Journal

ANNALS OF EMERGENCY MEDICINE
Volume 76, Issue 4, Pages 470-485

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.annemergmed.2019.09.001

Keywords

-

Funding

  1. Portola Pharmaceuticals
  2. Boehringer Ingelheim
  3. Janssen Pharmaceuticals
  4. Janssen Pharma
  5. Portola Pharma
  6. Daiichi-Sankyo
  7. CSL Behring
  8. AstraZeneca
  9. National Heart, Lung, and Blood Institute
  10. Portola
  11. Genentech
  12. Octapharma
  13. Abbott
  14. Braincheck
  15. Immunarray
  16. Janssen
  17. Ortho Clinical Diagnostics
  18. Relypsa
  19. Roche
  20. BMS

Ask authors/readers for more resources

Bleeding is the most common complication of anticoagulant use. The evaluation and management of the bleeding patient is a core competency of emergency medicine. As the prevalence of patients receiving anticoagulant agents and variety of anticoagulants with different mechanisms of action, pharmacokinetics, indications, and corresponding reversal agents increase, physicians and other clinicians working in the emergency department require a current and nuanced understanding of how best to assess, treat, and reverse anticoagulated patients. In this project, we convened an expert panel to create a consensus decision tree and framework for assessment of the bleeding patient receiving an anticoagulant, as well as use of anticoagulant reversal or coagulation factor replacement, and to address controversies and gaps relevant to this topic. To support decision tree interpretation, the panel also reached agreement on key definitions of life-threatening bleeding, bleeding at a critical site, and emergency surgery or urgent invasive procedure. To reach consensus recommendations, we used a structured literature review and a modified Delphi technique by an expert panel of academic and community physicians with training in emergency medicine, cardiology, hematology, internal medicine/thrombology, pharmacology, toxicology, transfusion medicine and hemostasis, neurology, and surgery, and by other key stakeholder groups.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available